AP-1060 is a newly established acute promyelocytic leukemia (APL) cell line from a multiple-relapse patient clinically resistant to both all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). The line was initially derived as a granulocyte colonystimulating factor-dependent strain that underwent replicative senescence and, following ethylnitrosourea treatment, as a phenotypically similar immortalized line. Immortalization was associated with broadened cytokine sensitivity but not growth autonomy, in contrast to three previously derived APL lines. Both the AP-1060 strain and line had shortened telomeres and low telomerase activity, while the line had higher expression of many genes associated with macromolecular synthesis. The karyotype was 46,XY,t(3;14)(p21.1;q11.2),t(15;17)(q22;q11) [100%]; the unique t(3;14) was observed in 4/9 t(15;17)-positive metaphase cells at previous relapse on ATRA therapy. The PML-RARa mRNA harbored a missense mutation in the RARaregion ligand-binding domain (Pro900Ser). This was associated with a right-shift and sharpening of the ATRA-induced maturation response compared to ATRA-sensitive NB4 cells, which corresponded to the transcriptional activation by PML-RARaPro900Ser of a cotransfected ATRA-targeted reporter vector in COS-1 cells. AP-1060 also manifested relative resistance to ATO-induced apoptosis at X1 lM, while 0.25 lM ATO stimulated limited atypical maturation. These findings suggest that AP-1060 will be useful for further assessing molecular elements involved in APL progression and drug response/resistance.
Introduction
A frequent attribute of acute myelogenous leukemia (AML) cells is the ability to grow autonomously in tissue culture, that is, in the absence of exogenously supplied hematopoietic growth factors (HGFs) or other cytokines. 1, 2 However, AML cells are quite heterogeneous in this respect, and this property is usually limited to a small population of leukemic progenitors. [2] [3] [4] Despite these autonomous growth properties, expansive immortalized growth of AML cells in vitro is rare even under highly favorable conditions, at least partly related to the rapid loss of telomerase activity/telomere length associated with spontaneous terminal differentiation and/or apoptosis. 5 In almost all instances, in vitro growth of AML cells can be stimulated by cytokines, as originally recognized using clonogenic assays for leukemic cell progenitors, [6] [7] [8] including autonomously growing AML cell lines, such as HL-60 and KG-1.
9,10 By judiciously applying cytokine supplements, an increasing number of cytokine-dependent AML cell lines have been developed (reviewed in Drexler et al 11 ) . These lines are most commonly dependent for growth on granulocyte-macrophage colonystimulating factor (GM-CSF) but are quite variable in their individual responsiveness to many cytokines (reference, Table 2 ). Loss of cytokine dependence in both fresh and culture-established AML cells has been associated with the endogenous production of HGFs and/or with the constitutive activation of mitogen-activated protein kinases. 2, 4, 12 However, the relationship of these alterations to the establishment of immortalized AML cell lines remains uncertain. 13 The AML subclass of t(15;17)/PML-RARa-positive acute promyelocytic leukemia (APL) is unique in its derivation from a committed myeloid progenitor cell.
14 This is associated with limited growth potential in vitro and with an inability to engraft in immunocompromised mice except under exceptional circumstances. 3, 15, 16 Despite this limited growth potential, three immortalized cell lines have been previously established from APL patient bone marrows. The first line, NB4, was initiated on a cytokine-producing monolayer but subsequently became growth autonomous, 17 while the other two lines, UF-1 and HT93, did not require a feeder layer for establishment. 18, 19 The NB4 and UF-1 lines were derived from patients who were clinically resistant to therapy with all-trans retinoic acid (ATRA), 17, 18 while the HT93 line was derived from a patient who had twice relapsed from chemotherapy but had not received ATRA. 20 Despite derivation from an ATRA-resistant patient, NB4 cells remained sensitive to the induction of terminal neutrophilic differentiation by ATRA, 17 although a variety of ATRA-resistant sublines have been selected. 21 Conversely, UF-1 cells are resistant to ATRA-induced maturation due to a mutation in the PML-RARa fusion gene, which was also present in APL cells from the patient source. 22 In the presence of ATRA, HT93 cells can be modulated to differentiate towards neutrophils by granulocyte colony-stimulating factor (G-CSF) but towards eosinophils by GM-CSF or IL-3. 19 The APLspecific t(15;17) chromosome translocation, which generates the PML-RARa fusion gene, was present in all three APL cell lines. [17] [18] [19] NB4 cells, which have a subtetraploid karyotype, contain two t(15;17) chromosomes, and all of the three cell lines contain several other cytogenetic abnormalities in addition to the t (15;17) .
Here, we report the establishment of a fourth APL cell line, AP-1060, from a multiple-relapse patient clinically resistant to both ATRA and arsenic trioxide (ATO), two bioeffectors with potent antileukemic activity specifically in APL. 23 Compared to NB4 cells, AP-1060 cells are moderately resistant to the in vitro effects of each of these compounds, in the case of ATRA due to the presence of a mutation in PML-RARa. Uniquely for APL lines, the AP-1060 line remains cytokine dependent for survival and growth. Further, it was derived in two stages: initially as a G-CSF-dependent cell strain (AP-1060S) and, after mutagenesis with ethylnitrosourea (ENU), as an immortalized line with broadened HGF responsiveness (AP-1060). Despite the difference in growth properties, only minor phenotypic differences were apparent between the strain and line, and the G-band karyotype of each was indistinguishable with one chromosome abnormality, a t (3;14) , in addition to the common APL-specific t (15;17) . These unique features suggest that the AP-1060 cell culture system will be useful for further dissecting molecular processes involved in APL progression and related to ATRA and ATO activity and resistance.
Materials and methods

Patient information
When the bone marrow used to initiate the AP-1060 cell line was obtained, the patient had relapsed for the fourth time after achieving an initial, transient clinical response on ATO therapy (Table 1 ) Three previous relapses followed hematologic complete remissions induced and consolidated with various chemotherapy þ ATRA regimens. After the third relapse from therapy which included 3 months of continuous ATRA, cytogenetic analysis demonstrated a t(3;14)(p21;q11.2) marker chromosome in 4/9 t(15;17)-positive metaphases; 2/4 t(3;14)-positive metaphases also contained an additional chromosome 13. After discontinuing ATRA and disease progression while off all therapy for about 3 weeks, repeat cytogenetic analysis prior to beginning ATO therapy showed an increase in the proportion of t(15;17)-positive metaphases from 9/20 (45%) to 15/15 (100%) but diminished frequency of the t(3;14) (4/9 to 0/15). Unfortunately, no assessable bone marrow metaphases were obtained after relapse on ATO treatment, although FISH analysis disclosed 62% t(15;17)-positive interphase cells.
Cell culture methods
The patient's bone marrow sample was obtained and utilized under institutional review board-approved protocols. 24 Suspension cultures of bone marrow mononuclear cells were performed in 24-well plates (Becton Dickinson/BD, San Jose, CA, USA) at 10 5 cells/ml in RPMI 1640 medium containing 10% FBS and penicillin/streptomycin (Life Technologies, Gaithersburg, MD, USA). 25 Selected wells were supplemented with the following single or combined HGFs: stem cell factor (SCF), 50 ng/ml (Immunex, Seattle, WA, USA); interleukin(IL)-1b, 50 ng/ml (R&D Systems, Minneapolis, MN, USA); IL-3, 25 ng/ ml (R&D); IL-6, 50 ng/ml (Immunex); G-CSF, 50 ng/ml (Amgen, Thousand Oaks, CA, USA); IL-11, 100 ng/ml (Genetics Institute, Cambridge, MA, USA). GM-CSF and Flt3 ligand used in subsequent experiments were obtained from R&D and Immunex, respectively. Cells were also seeded at 10 5 cells/ml in To derive the permanent cell line, AP-1060S cells at 2.5 Â 10 6 in IMDM containing 5% ALCM and 10% FBS were treated with 1 mM ENU (Sigma) for 48 h, washed with warm IMDM, maintained in suspension culture for 1 week and then plated into methylcellulose (MethoCult H4300; StemCells) supplemented with 5% ALCM at 4 Â 10 4 cells/ml. After 3 weeks, all cells that had survived and grown in methylcellulose were harvested and returned to suspension culture. The continuous suspension culture line AP-1060 was secured from pooled cells recovered after the third replating in methylcellulose. Subsequently, the line could be maintained in 5% CM from A5637 cells (ATCC) in place of ALCM. Multiple early-passage freeze stocks of both AP-1060S and AP-1060 cells, determined to be mycoplasma free (PCR ELISA kit, Boehringer-Mannheim, Indianapolis, IN, USA), were stored in liquid nitrogen.
Cytogenetic analysis
A standard Giemsa-banding technique (ISCN, 1978) was employed for numerical and karyotypic analyses. FISH analysis was performed using the LSI PML/RARA Dual Color Translocation Probe (Vysis, Downers Grove, IL, USA).
Telomere length and TRAP assays
For measurement of telomere length, genomic DNA was extracted from 2 Â 10 6 cells using phenol/chloroform and proteinase K. In total, 10 mg of DNA were digested with BglII and electrophoresed through a 0.7% agarose gel before Southern blotting. The blot was hybridized to a [g-32 P]ATP endlabeled telomere oligo-probe (TTAGGG) 4 . Autoradiography was performed for 2 days. The TRAP assay, which incorporates an internal PCR control, was performed as described. 26, 27 Evaluation of cell phenotype and response to ATRA and/or ATO All procedures have been previously described, including the evaluation of cytologic features by various stains and the performance of the nitroblue tetrazolium dye reduction (NBT) test, 25 and immunophenotyping by multiparameter flow cytometry, using a panel of monoclonal antibodies. 28,29. Evaluation of cell viability and apoptosis Cell viability was assessed by the trypan blue dye exclusion test (Life Technologies). 25 Apoptosis was assessed by a flow cytometric procedure as the fraction of cells with sub-G1 DNA content. 30 Cytospin preparations of cells were microscopically examined for characteristic signs of apoptosis after 
Molecular evaluation of PML-RARa
All procedures have been previously described, including evaluation of PML-RARa by RT-PCR, 25, 31 site-directed mutagenesis of PML-RARa, 24 assessment of transcriptional transactivation activity using a transient reporter cotransfection assay, 24 and assessment of the binding affinity of the corepressor N-CoR and the coactivators SRC-1 and p300 to the ligand-binding domain of wild-type or mutant PML-RARa/RARa using a GST pulldown or mammalian two-hybrid assay. 32 
Microarray analysis
RNA was extracted with Trizolt (Life Technologies) from late log-phase AP-1060S and AP-1060 cells. In all, 50 mg of each RNA were labelled with Cy5 or Cy3 (Amersham, Piscataway, NJ, USA) with reversal of labels in duplicate dual-labelling experiments on 9216 cDNA microarray slides provided by the Albert Einstein Cancer Center, Bronx, NY, USA. 33 Procedures for probe labelling, hybridization, array scanning and analysis were exactly as described. 34 
Results
Cell strain derivation
Following explantation into suspension culture, limited proliferation of the patient's bone marrow cells did not extend beyond 3 weeks in cultures supplemented with G-CSF, IL-3 or SCF (GM-CSF not tested). However, disperse cell growth was noted in methylcellulose cultures supplemented with 10% ALCM. On day 8, all cells were harvested and transferred to a suspension culture in ALCM-supplemented medium at 5 Â 10 5 cells/ml. This resulted in persistent cell survival but relatively static cell numbers until about the 12th week, when there was a sudden onset of exponential growth. This continued for several weeks but was succeeded by a gradual decline in replicative vigor. The total growth period was reproducibly limited to B17 cell doublings. Thus, this culture, which was preliminarily presented as the AP-1060 cell line (Kim et al, Blood 1998, 92, 609a abstract), was more properly a cell strain (renamed AP-1060S).
Immortalized cell line derivation
Many different conditions were tested to attempt to overcome the limited growth span of AP-1060S cells. This included the use of many HGF/cytokines, alone and in combination, and the utilization of CM from the human bladder carcinoma line A5637 35 and the mouse bone marrow stromal line MS-5 36 (or direct coculture with these monolayer cultures). Additionally, a subpopulation of the AP-1060S cells was successfully transduced with retroviral vectors containing telomerase (pBABE-HYGRO-hTert 37 and pMSCV-hTert-EGFP, our reconstruct from MIG1 38 ), as judged by the detection of mRNA for the linked hygromycin-resistance gene or visualization of cellular fluorescence from EGFP, but without stimulation of continuous cell growth. After failure of these conservative approaches, we mutagenized the AP-1060S cells with ENU followed by alternate growth in suspension and methylcellulose cultures (see Materials and methods). This resulted in the derivation of the permanent AP-1060 cell line from mixed clonogenic cells, which have been able to sustain growth in suspension culture for 41 year. Telomere length and telomerase activity 
Growth requirements and characteristics
Karyotypic analysis
The karyotype of both AP-1060S and AP-1060 cells was 46XY,t(3;14)(p21.1;q11.2),t(15;17)(q22;q11.2) (not shown), which was uniformly observed in several dozen metaphase cells analyzed. By standard Giemsa-band analysis, there was no discernible difference between AP-1060S and AP-1060 karyotypes. The t(3;14) was also observed in 4/9 t(15;17)-positive metaphase cells in the patient's bone marrow cells after a third relapse on continued ATRA therapy (Table 1) .
AP-1060 cell phenotype and immunophenotype
The APL cells from the AP-1060S and AP-1060 had a similar cytologic appearance (Figure 3b,c) . Typically, the cells showed irregular folded nuclei, frequently in a bi-or trilobed pattern.
There was a moderate amount of basophilic cytoplasm with some large azurophilic granules but no discernible Auer rods. They also manifested a minor subpopulation of smaller cells with less basophilic cytoplasm. The cytoplasm of some cells contained an increased number of vacuoles, mostly small, compared to the precultured cells. (Table 2) . AP-1060 cells (strain/marrow not tested) also lacked CD18 expression, another unique feature of APL among the myeloid leukemias.
39 CD38 and CD117, two notoriously weak antigens in APL, 29 were expressed strongly in the original cells but weakly and variably in the cultured cells. Furthermore, while APL cells typically present with the sialylated form of the carbohydrate antigen CD15, as reflected by differential reactivity with CD15/CD15s antibodies, 28, 29 CD15 appeared to be in the asialo-state in the original cells but was absent/nonreactive with either CD15 or CD15s antibody in the cultured cells. Uncommon for APL and AML cells in general, all three cell 
Gene expression profile of AP-1060 vs AP-1060S
As a first step in assessing differences that account for the enhanced growth and survival properties of the immortalized AP-1060 cells, a comparative analysis of mRNAs expressed by the line vs the strain was made using a 9216 cDNA microarray. In replicate experiments, 4651 spotted cDNAs (50.5%) yielded evaluable results in both experiments, and, of these, signals from the line compared to the strain registered a X2-fold increase in 496 instances (10.7%) or a X2-fold decrease in 244 instances (5.2%). A subset of these X2-fold differential signals represent transcripts for known genes, which have been subcategorized by function (Table 3) . 34 A notable difference between AP-1060 cells compared to AP-1060S cells was a high incidence of relatively increased In AP-1060, CD38 and CD117 expression generally was of weak intensity, the percentage of positive cells ranging from 0 to 99% on different days of testing.
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Y Sun et al transcript levels of genes related to increased DNA synthesis and cell cycle progression, 25/93 genes (27%) with a 42-fold difference ( Table 3) . As examples, DNA polymerase e, DNA topoisomerase II a, E2F-1 and Dp-2 transcripts were increased by 42-fold, while checkpoint suppressor 1 transcript was decreased by 42-fold. Similar differences in gene transcript levels favoring increased mitogen-activated protein kinase signalling pathways, RNA synthesis, protein synthesis and turnover and metabolic enzyme activity were associated with the AP-1060 cell line (see online database). In contrast, only 3/ 23 gene transcripts (13%) related to apoptosis differed by 42-fold between the cell strain and line (Table 3) . Also, there was no apparent consistency in the pattern of the modest differences in proapoptotic vs antiapoptotic transcript levels, for example, caspase 3 was slightly increased, while caspases 9 and 10 were decreased. Owing to their under-representation in the cDNA microarray, we extended the analysis of apoptosis-related gene transcripts, using 3 commercially available ribonuclease protection assay kits (BD PharMingen, kits hAPO-2c, hAPO-3d and hAPO-5), but found only minor differences in the expression levels of 30 proapoptotic (including Bax, Bak, Bad, caspase 8 and Fas) or antiapoptotic genes (including Bcl2, Bcl-X L , Mcl1, XIAP, NAIP and C-IAP-1&2) (not shown). Overall, these data suggest that the increased survival and immortalization of the AP-1060 line was primarily related to increased replicative vigor.
Only a small number of myeloid differentiation markers were present in the cDNA microarray but, as noted for apoptosisrelated genes, the quantitative changes between the line and strain were minor compared to the changes in macromolecular synthesis/metabolism gene-related transcript levels. Of note, however, transcript levels for two primary granule matrix proteins (cathepsin G and bacterial/permeability increasing protein), as well as, for CD34 antigen were somewhat higher in the line, while transcript levels of three genes associated with later stages of terminal neutrophil differentiation (transcobalamin 1, grancalcin and CD11b) were slightly diminished in the line compared to the strain. The latter findings were supported by the results for three other gene transcripts associated with intermediate to late neutrophil differentiation [41] [42] [43] but in which only single evaluable line:strain determinations were available (excluded from Table 3) : SNAP-23, 0.56; gelatinase B, 0.54; and a defensin 3, 0.34. Although additional studies are clearly needed in the absence and presence of terminal maturation inducers in order to assess the neutrophil differentiation characteristics of AP-1060 cells, the overall data suggest that the line is shifted to a slightly earlier maturation stage.
Aberrant maturation response to ATRA associated with mutation in PML-RARa
Treatment with X100 nM ATRA stimulated the terminal differentiation of virtually 100% of cells from either AP-1060 or AP-1060S cells into neutrophilic granulocytes (Figure 3d,e) . Notably, the dose-response to ATRA was atypically sharp with no response measurable by the NBT test at 10 nM ATRA and with a virtually complete response by 100 nM ATRA, which contrasted with the 2-3 log dose-response of NB4 cells (Figure 4a) .
The cytological and functional response of AP-1060 cells was paralleled by selective modulation of membrane antigens in response to ATRA (Table 4a) . A decrease in CD117 and an increase in CD38 expression were already observed at 10 nM ATRA, while induction of markers of myeloid maturation, including CD65, CD65s, CD15, CD15s, CD11b and CD18, was observed only starting with 50 nM ATRA. At 100 nM, ATRA elicited increased fluorescence intensity of antibody binding as well as an increased percentage of positive cells, suggestive of higher antigen density. Notably, CD11a, a leukocyte integrin expressed throughout all stages of normal myelopoiesis, could not be induced by ATRA, suggesting incomplete maturation. Additionally, there was no apparent downregulation of the primary granule protein myeloperoxidase or induction of the secondary granule protein lactoferrin or of the prototype monocytic marker CD14 (not shown).
RT-PCR analysis of RNA from the AP-1060 cells disclosed the long(L)-form of the PML-RARa fusion gene. Allele-specific sequence analysis of cDNA representative of the C-terminal of the RARa region of PML-RARa revealed a C to T substitution in nucleotide 2780. 44 This produces a missense mutation in codon 900, corresponding to codon 407 of normal RARa, 45 which changes a proline to a serine residue (Pro900Ser). The same mutation was detected in RNA from the patient's preculture bone marrow cells. 24 In cotransfection experiments of this mutant PML-RARa in the pSG5 expression vector and of a reporter vector containing a classical direct repeat retinoic acid response element (DR5-tk-luc), 24 the transcriptional transactivation response to ATRA in COS-1 cells closely paralleled the AP-1060 cell ATRA differentiation response (Figure 4b ).
The Pro900Ser mutation had only a minor effect on the binding of subinducing 10 nM ATRA to the fusion protein. 24 However, it increased by 410-fold the ATRA concentration required to dissociate the corepressor N-CoR from Pro407Ser mutant compared to wild-type PML-RARa (Figure 5a ). Despite the very limited dissociation of N-CoR at 10 À6 M ATRA, recruitment of the coactivators SRC-1 ( Figure 5b ) and p300 (not shown) was observed at X10-fold lower ATRA concentrations. Both the corepressor and coactivator results were confirmed at 10 À6 M ATRA, using the mammalian two-hybrid assay (not shown). 32 Differential effects of high and low ATO concentrations AP-1060 cells were less sensitive to ATO-induced apoptotic cell death than NB4 cells at ATO concentrations 41 mM (Figure  6a,b) . In NB4 cells, the apoptosis was associated with G2/M cell cycle arrest, maximum after 24 h culture at 1-2.5 mM ATO, while little or no effect was noted in AP-1060 cells (not shown). A low concentration of ATO (0.25 mM) alone produced a modest (CD38, CD15, CD15s) or no induction of myeloid differentiation markers (CD65, CD11b, CD18), and, after 5 or more days of culture, 0.25 mM ATO elicited a modest increase in nuclear condensation and segmentation (Figure 3h ) without NBT positivity (Figure 6c ). In combination with 50 or 100 nM ATRA, 0.25 mM ATO slightly but reproducibly reduced the ATRAinduced expression of myeloid maturation markers (Table 4b) , which was paralleled by an inhibitory effect of ATO on ATRAinduced NBT positivity (Figure 6c ).
Discussion
This report describes a newly established APL cell line AP-1060 derived from a multiple-relapse patient clinically resistant to the two therapeutic agents, ATRA and ATO, that are uniquely effective in APL. 23 In vitro sensitivity testing indicated that AP-1060 cells are partially resistant to both of these agents. This suggests that these cultured APL cells captured molecular APL cell line AP-1060 Y Sun et al Table 3 Comparison of cell cycle-, apoptosis-and neutrophil differentiation-related gene expression levels between AP-1060 and AP-1060S cells
Functional category
Gene name Normalized signal ratio of line to strain All named genes in category; 3/23 (13%) with X2-fold decrease in line vs strain. c All named genes in category, 2/12 (17%) with X2-fold decrease in line vs strain; inclusion in category based on references Cowland and Borregaard 41 and Bainton.
42 aberrations contributing to the clinical resistance to these agents, although detailed consideration further suggests that these resistance characteristics may not fully account for the clinical resistance to either agent. The differentiation dose-response curve of AP-1060 cells to ATRA was markedly sharpened and shifted to the right compared to that of ATRA-sensitive NB4 cells (Figure 4a ). Nevertheless, a complete differentiation response was achieved at 100 nM ATRA, an achievable concentration in blood plasma on a standard oral ATRA regimen. 46 These considerations raise questions about the significance of such a modest decrease in APL cellular ATRA sensitivity for the apparent clinical refractoriness of the patient to ATRA therapy (Table 1) . In this regard, AP-1060 was derived from a bone marrow specimen obtained 5 months after the last course of ATRA therapy and after intervening cytoreduction by ATO therapy. Thus, it is possible that AP-1060 was isolated from a different subclone than an antecedent more-strongly ATRA-resistant subclone(s) that predominated following disease progression on ATRA therapy. This possibility is suggested by the cytogenetic finding at the time of ATRA relapse that the t (3;14) , which is uniformly present in AP-1060 cells, was only observed as a solitary marker in 2/9 t(15;17)-positive cells, while two other t(3;14)-positive cells contained an additional chromosome 13 and 5/9 t(15;17)-positive cells lacked t(3;14) (Table 1) . Alternatively, the clinical ATRA resistance may have been related to systemic defects in ATRA pharmacology 46 that magnified the effect of the modest decrease in APL cell ATRA sensitivity produced by the PMLRARaPro900Ser mutation.
The PML-RARaPro900Ser mutation occurred in the same site as a missense mutation in an ATRA-resistant NB4 subline but with a different amino-acid substitution (Pro900Leu). 47 Unlike AP-1060 cells, this subline had strong ATRA resistance, which could be partially overcome by combined treatment with the cAMP analog 8-(4-chlorophenylthio)-cAMP (8-CPT-cAMP). 47 Notably, PML-RARaPro900Leu markedly decreases ATRA-binding and transcriptional transactivation activity (D Zhou, unreported data), and experimental mutation of the corresponding proline to alanine (Pro407Ala) in normal RARa also markedly decreased the binding of ATRA and, even more so, of 9-cis retinoic acid (9cRA). 48 We, however, found no differences in the response of AP-1060 cells to ATRA or 9cRA78-CPT-cAMP (unpublished data). Thus, different amino-acid substitutions for Pro900/407 can have quite different functional consequences. Additionally, we found that, although the decrease in ATRA binding by 24 and transcriptional transactivation of PML-RARaPro900Ser was quite modest (in agreement with the maturation ATRA dose-response of AP-1060 cells; Figure 4 ), the dissociation of the corepressor N-CoR from the mutant PML-RARa was minimal up to 1 mM ATRA (Figure 5a ). However, we further found that PML-RARaPro900Ser was able to recruit the coactivator SRC-1 (and p300) at p10 À7 M ATRA (Figure 5b ), an effective inducing concentration. This is similar to a previously reported observation for an alternative PML-RARa mutation, which was speculated to account for effective transcriptional activation of a PML-RARa target gene in spite of incomplete ATRA-induced corepressor dissociation. 49 AP-1060 cells were also partially resistant to the in vitro effects of ATO compared to ATO-sensitive NB4 cells. Logically, this might be related to the derivation of AP-1060 cells from a bone marrow specimen obtained at disease relapse (Table 1) . This comparative ATO resistance was most apparent at a relatively high ATO concentration (2.5 mM), which induced apoptosis in 450% of NB4 cells but o20% of AP-1060 cells above background after 48 h exposure (Figure 6b ). NB4 cell apoptosis was associated with a G2/M-phase cell cycle arrest, which was maximal 24 h after treatment with 2.5 mM ATO (not shown) indicating, in agreement with a recent report, 50 that cell cycle arrest may precede apoptosis. Little or no such effect was noted in AP-1060 cells, suggesting that this could be related to the lower sensitivity of AP-1060 cells to ATO-induced apoptosis. The relevance of these observations to clinical ATO resistance is uncertain, although arsenic plasma levels in the 1-2 mM range have been described in patients receiving comparable 51 or somewhat higher 52 ATO doses than administered to this patient (0.15 mg/kg/day). 53 Further studies are required to determine whether an in vivo mechanism, perhaps involving modulation of effective intracellular concentrations of ATO or its derivatives, 54 could link cellular defects to clinical ATO resistance. Table 4 ), as previously reported for NB4 cells. 55 Additionally, ATO consistently had a modest inhibitory effect on ATRA-induced AP-1060 cell maturation (Figure 6c and Table 4b ). This resembled a similar negative interaction of ATO-ATRA reported for NB4 cells, 56, 57 although other investigators have reported contrary results. 58 These results are of some concern, since ATRA-ATO combinations are in current clinical use in APL. 23 However, there are many possible mitigating factors in vivo, including drug dose and schedule, and preclinical trials of the combined agents in mice have so far provided evidence for a positive rather than negative in vivo interaction. 57, 59, 60 The two-stage derivation and continued HGF dependence of AP-1060 cells is unusual and differs from the establishment history of three previously reported APL cell lines. [17] [18] [19] Although a relatively static incubation phase of approximately 3 months occurred prior to the onset of exponential cell growth in all instances, this did not result in immortalization of AP-1060S, as occurred in the three antecedent lines. AP-1060S cells gradually lost replicative vigor over B17 cell generations, attended by nonspecific cell degenerative changes but not terminal maturation (Figure 3g ). This process was accompanied by marked telomere shortening and telomerase activity diminution compared to the preculture bone marrow APL cells (Figure 2 ). Similar observations have been reported for other forms of myeloid leukemia cells after culture for up to 4 weeks, 5 although the in vitro expansion of AP-1060S cells was considerably greater over a 7-8-week growth period. This overall pattern is typical for the process of replicative senescence, which has been most thoroughly documented in monolayer cultures of epithelial cells. 61, 62 An important conclusion of these studies is that under most circumstances replicative senescence involves limiting factors in addition to diminished telomerase activity, including activation of cell cycle inhibitory genes. 63, 64 Conversely, breaking the senescence barrier in order to immortalize cells requires the inactivation of these cell cycle inhibitory genes. 65, 66 The latter mechanism likely accounts for the immortalization of AP-1060 cells after ENU mutagenization, since compared to AP-1060S cells, the established line cells showed a marked derepression of genes associated with cell cycle progression and DNA synthesis (Table 3 ), but with little or no secondary change in telomere length or telomerase activity (Figure 2 ). Despite having greatly increased replicative potential compared to AP-1060S cells, AP-1060 cells retained an absolute dependence on HGFs for survival and growth. This suggests that the signal transduction pathway from the membrane growth factor receptor(s) is essentially intact, although there was a change from narrow dependence of AP-1060S cells on G-CSF to a broader capacity of AP-1060 cells to proliferate nearly as well in GM-CSF-supplemented or IL-3-supplemented medium (Figure 1 ). This effect may simply indicate increased expression of the membrane receptors for these HGFs or the increased general replicative capacity of AP-1060 cells, and it does not affect the interpretation that the central cell cycle mechanism remains under peripheral control.
We speculate that the novel t(3;14)(p21.1;q11.2), the only cytogenetic abnormality identified by G-band analysis in addition to the APL-specific t(15;17)(q22.2;q11.2), may be related to the ability of the AP-1060S cells to initially propagate in vitro, a rare event for APL cells. In part, this speculation is based on a previous report of another unique secondary chromosome translocation in the APL cell line HT93A, a t(1;12)(q25;p13), which generated the fusion protein, ETV6/ ARG. 20 This constitutively activated Abelson-related gene (ARG) tyrosine kinase, which had the capacity to induce growth factor independence of the rodent hematopoietic line Ba/F3 and to transform Rat-1 fibroblasts. 67 Although these findings do not prove that the ETV6/ARG fusion protein was a central element in establishment of the growth factor-independent HT93 cell line, this seems a reasonable possibility given the evidence for the Mean values from two (0.25 mM ATO+50 nM ATRA) or three (0.25 mM ATO+100 nM ATRA) experiments, respectively. c Note: in this set of experiments, CD117 expression was virtually undetectable.
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Y Sun et al role of constitutively activated kinases in autonomous leukemic cell growth. 68 If this model applies to the AP-1060 system, then whatever growth impetus was imparted by the t(3;14) to AP-1060S cells was insufficient to provide either growth factor independence or immortalization. Since mutagenization then produced immortalization but not growth factor independence of the AP-1060 cell line, this suggests that separate events determine these properties.
In summary, the AP-1060 culture system has a number of unique features that may be of value in further investigating molecular, pharmacological and biological abnormalities that can affect APL cells. These include: an aberrant dose-response to ATRA involving a mutant receptor, which may facilitate the investigation of elements involved in ATRA-targeted transcriptional gene regulation leading to terminal differentiation; an apparent defect in ATO-induced cell cycle arrest, which may provide information about intermediate steps leading to apoptosis; an apparently more mature cytological phenotype than NB4 cells, which may be useful for studying later phases of neutrophil maturation; a remarkable preservation of phenotype between AP-1060S and AP-1060 cells despite major differences in macromolecular synthesis and metabolism, which may provide information about the relationship of these coexisting features under baseline and pharmacological treatment conditions; a replicative senscence response of AP-1060S cells, which may provide information about this process in myeloid leukemia cells; and the acquisition of immortality by AP-1060 cells without major changes in telomerase/telomeres or loss of growth factor dependence, which may provide further insights into mechanisms regulating APL cell proliferation.
Figure 5
Impaired ATRA-dependent dissociation of corepressor N-CoR from (a) and discordant ATRA-recruitment of coactivator SRC-1 to (b) mutant PML-RARaPro407Ser. Partial N-CoR or SRC-1 proteins were expressed in bacteria as GST fusion proteins, mixed with 35 Smethionine-labelled PML-RARas or RARa, incubated with GST-NCoR/SRC-1 affinity matrices and analyzed in pulldown assays, as detailed in reference Guidez et al. 32 The figure shows autoradiographs of SDS-PAGEs of radiolabelled PML-RARas or RARa bound to the affinity matrix in the absence or presence of increasing ATRA concentrations. 
